Alvimopan

CHEMBL270190 Phase 4 Approuvé Small molecule

Half-Life

—

Bioavailability

—

Protein Binding

—

Molecular Weight

424.5 g/mol

LogP

1.7

Phase

4

A peripherally acting mu-opioid receptor antagonist that blocks opioid effects specifically in the gut without crossing into the brain, used to accelerate the recovery of bowel function after bowel surgery. By restoring normal gut motility in patients who receive opioid pain medications after operations, it helps reduce the duration of post-surgical paralytic ileus.

Masse moléculaire

424,5000 g/mol

LogP

1,70

TPSA

89,90 Å²

Règle des 5 de Lipinski

Conforme

Aires thérapeutiques

Ovarian Cancer Pancreatic Cancer Bladder Cancer Thyroid Cancer Pain Management Non-Small Cell Lung Cancer Breast Cancer Chronic Pain Prostate Cancer Colorectal Cancer

Mécanisme d'action

Binds to mu (μ), kappa (κ), and/or delta (δ) opioid receptors in the central and peripheral nervous system, mimicking endogenous endorphins. Activation of these G-protein-coupled receptors inhibits pain signal transmission and modulates the emotional response to pain.

Pharmacokinetics (PK)

Pharmacodynamics (PD)

Mécanisme

Binds to mu (μ), kappa (κ), and/or delta (δ) opioid receptors in the central and peripheral nervous system, mimicking endogenous endorphins. Activation of these G-protein-coupled receptors inhibits pain signal transmission …

Structure 2D

SVG PNG

Cite this structure

Embed this structure

SMILES

C[C@H]1CN(C[C@H](Cc2ccccc2)C(=O)NCC(=O)O)CC[C@@]1(C)c1cccc(O)c1

InChI

InChI=1S/C25H32N2O4/c1-18-16-27(12-11-25(18,2)21-9-6-10-22(28)14-21)17-20(24(31)26-15-23(29)30)13-19-7-4-3-5-8-19/h3-10,14,18,20,28H,11-13,15-17H2,1-2H3,(H,26,31)(H,29,30)/t18-,20-,25+/m0/s1

Molecular Formula

C25H32N2O4

HBD / HBA

3 / 5

Liaisons Rotatives

8

Atomes Lourds

31

No targets recorded

Target interaction data is not yet available for this drug.

No interactions recorded

Drug interaction data is not yet available for this compound.

No side effects recorded

Side effect data is not yet available for this drug.

Foire aux questions

A peripherally acting mu-opioid receptor antagonist that blocks opioid effects specifically in the gut without crossing into the brain, used to accelerate the recovery of bowel function after bowel surgery. By restoring normal gut motility in patients who receive opioid pain medications after operations, it helps reduce the duration of post-surgical paralytic ileus.

Binds to mu (μ), kappa (κ), and/or delta (δ) opioid receptors in the central and peripheral nervous system, mimicking endogenous endorphins. Activation of these G-protein-coupled receptors inhibits pain signal transmission and modulates the emotional response to pain.

Yes, Alvimopan is an approved drug. It has reached clinical phase 4. It is classified as a Small molecule.

{# References & Data Sources section for drug detail pages. Renders standard pharmacological database links plus the drug's data_sources field. #}

References & Data Sources

ChEMBL — European Bioinformatics Institute (EBI). CHEMBL270190. Open-access bioactivity database.
PubChem — National Center for Biotechnology Information (NCBI). CID 5488548. Chemical information database.

Data aggregated from publicly available pharmacological databases. Last updated 2026-03-04.

PillFYI

Vous cherchez des informations accessibles aux patients ?

Alvimopan sur PillFYI

Structure

Données Clés

Formule: C25H32N2O4

Liens externes

Cite

BibTeX, APA, MLA, Chicago, IEEE, Harvard

Avertissement médical

This content is for educational and informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making medication decisions.

Data sources: ChEMBL, PubChem, DailyMed.